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In this study, several workﬂows to analyze human plasma proteins with RP-LC MS/MS are
evaluated.  The impact of depletion of abundant proteins on the plasma proteome coverage
was  assessed together with the duration of RP-LC separation. An additional upstream liquid-
based  fractionation was  evaluated. The applicability and feasibility of these technologies in
large-scale clinical studies with respect to effort, throughput, and outcome are discussed.
Label-free  and isobaric tagging-based quantiﬁcations are examined in this perspective. We
demonstrate that, despite the great improvement of proteomic technologies, signiﬁcantBiomarker
Diagnosis
Liquid chromatography
Mass  spectrometry
trade-offs  between effort and yield are still challenging the discovery of protein biomarkers
in  blood plasma.
© 2013 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). 
formed  using targeted approaches in an increasing number
Open access under CC BY-NC-SA license.Shotgun proteomics
1.  Introduction
Because of its minimally invasive accessibility and its ready
availability, blood is the most preferred and used human body
ﬂuid  to be measured in routine clinical practice. Moreover,
blood perfuses all body tissues and contains, for instance,
proteins secreted, shed or released from cells and tissues. Its
composition is therefore relevant as an indicator of the over-
all  physiology of an individual [1]. The clinical deployment
of  human plasma protein markers for disease diagnosis, as
well  as health/disease prognosis and monitoring is in great
demand  and requires increased translation of candidates. By
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bâtiment  H, 1015 Lausanne, Switzerland. Tel.: +41 21 632 6114.
E-mail  addresses: loic.dayon@rd.nestle.com, loic.dayon@gmail.com
2212-9685 © 2013 The Authors. Published by Elsevier B.V. on behalf of European Proteo
http://dx.doi.org/10.1016/j.euprot.2013.08.001contrast, the identiﬁcation of novel biomarkers in human
plasma  is highly challenging and the rate of transfer of can-
didates  into the clinics has lagged behind expectations [2].
In  protein biomarker discovery projects, body ﬂuids and/or
tissues  are usually ﬁrst used to generate lists of biomarker
candidates, classically by comparison of case and control sam-
ples,  more  recently also in longitudinal studies, in which
each  “case” subjects is its own control. To reﬁne the list of
putative  biomarkers, an analytical veriﬁcation step is then per-e of Health Sciences SA, Campus EPFL, Quartier de l‘innovation,
 (L. Dayon).
of  plasma samples (typically tens to hundreds). Ultimately,
clinical validation of these analytically veriﬁed candidates
in  blood is performed in large cohorts to demonstrate the
mics Association (EuPA). Open access under CC BY-NC-SA license.
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tility, speciﬁcity and sensitivity of a biomarker or a panel of
iomarkers and to show their clinical relevance as prognostic
r diagnostic tools. The veriﬁcation and validation steps often
equire the development of assays, such as enzyme-linked
mmunosorbent assays (ELISA) or selected-reaction monitor-
ng (SRM) mass spectrometry (MS)-based assays that require
ime, investment, and expertise for execution and, possibly,
lso upstream development [3]. The opportunity to perform
he ﬁrst-stage screening in a higher number of samples may
elp increase the statistical signiﬁcance of the discovery ﬁnd-
ngs and reduce the number of “pilot” assays to be developed,
hich again requires substantial resources. Especially in view
f the latter aspect, analytical throughput of the proteomic
iscovery workﬂow is an important aspect to be considered
4].
The proteomic analysis of blood plasma with MS is a chal-
enging task. The high complexity and wide dynamic range of
roteins as well as the presence of a few proteins at very high
oncentrations complicate the deep proﬁling of the human
lasma proteome. Indeed, the concentrations of individual
roteins span 10–12 orders of magnitude and abundant pro-
eins, such as albumin, represent more  than 99% of the total
ulk mass of protein content [5,6]. In shotgun proteomics, the
ost abundant tryptic peptides dominate the MS analysis and
ide the less abundant ones, which often derive from proteins
f biological importance.
The removal of abundant proteins with immuno-afﬁnity
aits can signiﬁcantly reduce the dynamic range and also
he complexity of plasma protein samples [4,5,7,8]. Addi-
ional fractionation methods, either electrophoresis- or
hromatography-based, are used to improve coverage of the
lasma proteome. Nonetheless, all these sample preparation
teps add to the overall analysis time, both at sample hand-
ing and subsequent mass spectrometric level. To analyze a
arge number of samples, sufﬁcient throughput is necessary,
imiting the applicability of extensive fractionation before MS
nalysis.
We evaluated several proteomic workﬂows for the analysis
f human blood plasma samples. We  used a commer-
ial source of plasma obtained from pooled human blood.
irst, depletion of abundant proteins was assessed. One or
wo/tandem depletion stages (i.e., immuno-afﬁnity removal
f some abundant proteins) were performed as previously
eported by others [5,7]. For the so-called tandem depletion,
he plasma sample was loaded a ﬁrst time on the deple-
ion cartridge and the ﬂow-through was loaded again on
he same depletion cartridge after its regeneration. Second,
he duration of the gradient and the length of the column
sed for on-line reversed-phase liquid chromatography (RP-
C) before MS were varied (i.e., 70 min  separation with a
5 cm column and 150 min  separation with a 50 cm column).
t last, two dimensional (2D) RP/RP-LC with ﬁrst dimen-
ion fractionation of the sample at basic pH, followed by
 second at the usual acidic pH, was evaluated for deeper
roteome coverage [9]. To assess relative protein quantiﬁca-
ion between samples, both label-free and isobaric tagging
pproaches were considered. All these workﬂows were dis-
ussed in terms of efforts (i.e., invested time and cost),
hroughput, and plasma proteome coverage as an outcome.
e argue that advised combination of such technologies is s 1 ( 2 0 1 3 ) 8–16 9
relevant for large clinical studies in the context of biomarker
discovery.
2.  Materials  and  methods
2.1.  Material
Iodoacetamide (IAA), tris(2-carboxyethyl) phosphine
hydrochloride (TCEP), triethylammonium hydrogen carbonate
buffer (TEAB) 1 M pH = 8.5 and sodium dodecyl sulfate (SDS)
were purchased from Sigma (St. Louis, MO, USA). Formic acid
(FA, 99%) was from BDH (VWR International Ltd., Poole, UK).
Hydroxylamine solution 50 wt% in H2O (99.999%) was from
Aldrich (Milwaukee, WI,  USA). Water (18.2 M cm at 25 ◦C) was
obtained from a Milli-Q apparatus (Millipore, Billerica, MA,
USA) and acetonitrile was from BDH. The PROT20S kit was
purchased from Sigma and used for abundant-protein deple-
tion. The sixplex tandem mass tags (TMTs) were purchased
from Thermo Scientiﬁc (Rockford, IL, USA). Sequencing grade
modiﬁed trypsin was from Promega (Madison, WI,  USA).
Lyophilized Human plasma (Sigma, Lot 070M7009) containing
3.8% trisodium citrate as anti-coagulant, and obtained from
pooled human blood, was re-suspended in 1 mL H2O. Aliquots
were kept at −20 ◦C.
2.2.  Sample  preparation
Human plasma sample was depleted using the PROT20S kit
according to the manufacturer’s instructions with 10 consec-
utive depletions of 8 L of plasma. The protein recovery before
and after one or two stages of depletion appears in Table 1. The
protein concentration in the studied samples was determined
at 280 nm in triplicate with a NanoDrop apparatus (Thermo
Scientiﬁc) [10]. Reduction, alkylation, and protein digestion
was performed as previously reported [11]. Brieﬂy, each sam-
ple (i.e., 10 to 100 g of lyophilized proteins) was dissolved in
95 L of TEAB 100 mM and 5 L of SDS 2%. A volume of 5.3 L
TCEP 20 mM was added and incubation was performed for 1 h
at 55 ◦C. A volume of 5.5 L IAA 150 mM was added (incuba-
tion for 1 h in the dark). Enzymatic digestion was performed
by addition of 10 L trypsin at 0.25 g L−1 in TEAB 100 mM
and incubation overnight at 37 ◦C.
TMT labelling was performed by addition of 0.8 mg  sixplex
TMT  reagent in 41 L CH3CN (incubation for 1 h at room tem-
perature). After reaction, a volume of 8 L hydroxylamine 5%
in H2O was added to each tube to react for 15 min.
All samples were puriﬁed with Oasis HLB cartridges (1cc,
30 mg)  from Waters (Milford, MA, USA) followed by strong
cation-exchange solid-phase extraction using home-prepared
columns packed with SP Sepharose Fast Flow (Sigma). Samples
were then evaporated to dryness before storage at −20 ◦C.
2.3.  RP-LC  and  RP/RP-LC  MS/MS
The samples were dissolved in H2O/CH3CN/FA 96.9/3/0.1 for
RP-LC MS/MS analysis. LC MS/MS  was performed on an LTQ
orbitrap (OT) Elite from Thermo Scientiﬁc (San Jose, CA,
USA) equipped with an Easy-nLC 1000 (Thermo Scientiﬁc)
for 70 min  separation or an Ultimate 3000 RSLC nano system
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Table 1 – Protein amounts and yields obtained after 1stage or 2 stages of abundant-protein depletion. Starting from 80 L
of crude plasma, 10 depletion processes of 8 L crude plasma were performed with the ProteoPrep® plasma
immunodepletion kit from Sigma (see Section 2) to obtain the pooled depleted plasma sample, so-called 95% depleted. A
unique second depletion stage was performed on half of the plasma sample 95% depleted, to obtain the depleted plasma
sample, so-called 99% depleted.
Sample Volume (L) Concentration (g L−1) Amount (g) Yield (%)
Plasma 80 43.72 ± 0.35 3497 100
Plasma, 95% depleted 620b 0.847 ± 0.02 525 15
Plasma, 99% depleteda 220b 0.40 ± 0.01 87 5
 proc
ed froa The equivalent of half of the sample followed the second depletion
b Volumes obtained after buffer exchange. These values were obtain
(Thermo Scientiﬁc) for 150 min  separation. Proteolytic pep-
tides (∼1 g) were trapped on an Acclaim Pepmap 75 m × 2 cm
(C18, 3 m,  100 A˚) pre-column (Thermo Scientiﬁc). Following
washing, peptides were separated on an Acclaim PepMap RSLC
75 m × 15 or 50 cm (C18, 2 m,  100 A˚) column (Thermo Sci-
entiﬁc) coupled to a stainless steel nanobore emitter (40 mm,
OD 1/32′′) (Thermo Scientiﬁc). The analytical separation was
run either for 70 or 150 min  using a gradient that reach 30%
of CH3CN after 60 and 140 min  respectively and 80% after
70 and 150 min  respectively. A ﬂow rate of 220 nL min−1 was
used. For MS1  survey scans, the OT resolution was 60,000 and
the ion population was 1 × 106 with an m/z window from 300
to 1500. For MS2  in the LTQ with collision induced dissocia-
tion (CID), the ion population was 1 × 104 (isolation width of
2 m/z  units) with a maximum injection time of 150 ms.  For
MS2  detection in the OT with higher-energy collisional disso-
ciation (HCD), the ion population was set to 1 × 105 (isolation
width of 2 m/z units), with a resolution of 15,000, ﬁrst mass
at m/z  = 100 Th, and a maximum injection time of 750 ms.  A
maximum of 20 precursor ions (most intense) were selected
for CID activation. CID was performed at 30% of the nor-
malized collision energy (NCE). A combined CID/HCD method
with a maximum of 10 precursor ions (most intense) was
used to analyze TMT-labelled samples as previously described
[11,12]. In this case, CID was performed at 30% of the NCE
while HCD was performed at 60%. Dynamic exclusion was
set for 60 s within a ±5 ppm window. The lock mass at
m/z  = 445.1200 Th was used. Each sample was analyzed in trip-
licate.
For upstream sample fractionation of the sample with
RP-LC at basic pH (pH = 9.6), ∼24 g of each plasma protein
digest (previously diluted at 2.4 g L−1 in ammonium formate
20 mM,  pH 9.6 (solvent C)) was loaded on a 300 m × 15 cm
Acclaim PA II column (C18, 3 m,  120 A˚) from Thermo Scien-
tiﬁc. The separation was performed with an Ultimate 3000
RSLC NCP system (Thermo Scientiﬁc) for 38 min  with a gra-
dient of solvent C and solvent D (ammonium formate 20 mM,
pH 9.6 with 80% CH3CN) at a ﬂow rate of 6 L min−1. The gra-
dient was performed as follows: 0–2 min  95% C and 5% D, then
to 82% C and 18% D at 10 min, 60% C and 40% D at 15 min, 10%
C and 90% D from 18 to 25 min, and 95% C and 5% D from 25
to 38 min. Twelve fractions were collected from 12 to 27 min.
Samples were then evaporated to dryness before storage at
◦−20 C. Each fraction was diluted in 20 L of H2O/CH3CN/FA
96.9/3/0.1 (see above). One fourth (i.e., 5 L of each fraction) was
analyzed by RP-LC MS/MS  with a 70 min  gradient in duplicate
(see above for details).ess.
m NanoDrop readouts (see Section 2).
2.4.  Data  analysis
Proteome Discoverer 1.3 (version 1.3.0.339, Thermo Scien-
tiﬁc) was used as raw data post-processing interface with
the possibility to select scan events for peptide/protein
identiﬁcation and/or quantiﬁcation. Identiﬁcation was per-
formed in the Swiss-Prot database (SwissProt 2012 07) with
Homo sapiens taxonomy (20,232 sequences). Mascot (version
2.4.0, Matrix Sciences, London) was used as search engine.
Variable amino acid modiﬁcation was oxidized methionine.
Carbamidomethylation of cysteines was set as ﬁxed modiﬁ-
cation. In case of TMT  sixplex labelled samples, TMT-labelled
peptide amino terminus and TMT-labelled lysine (+229.163 Da)
were set as ﬁxed modiﬁcations. Trypsin was selected as the
enzyme, with one potential missed cleavage. Peptide and frag-
ment ion tolerance was respectively 10 ppm and 0.6 Da.  All
ﬁles were loaded in Scaffold 3.6.5 (Proteome Software, Port-
land, OR, USA) to visualize and validate the results. Peptide
and protein thresholds were 95.0% and 99.0% respectively with
a 2 unique peptide criterion to report protein identiﬁcation
(see Supplementary data).
3.  Results
In this study, 3 sample preparation workﬂows were conducted
and compared using aliquots of the same commercial pooled
human plasma sample: (i) one consisted of a direct processing
of the sample without any abundant-protein depletion; (ii) the
second included abundant-protein depletion before further
processing of the plasma sample and LC MS/MS  analysis; and,
(iii) the third workﬂow comprised two consecutive immunode-
pletion steps (i.e., successive load and reload of the sample on
the same depletion cartridge; see Section 2) to increase the
efﬁciency of abundant-protein removal. For each sample, pro-
teins were then reduced, alkylated and digested with trypsin.
Half of the samples was labelled with a sixplex tandem mass
tag (TMT) reagent, while the other half was kept unmodiﬁed
as in a label-free approach. As illustrated in Fig. 1, six differ-
ent samples were obtained and puriﬁed as described in the
Material and Methods section before further LC MS  analysis.
3.1.  Abundant-protein  immunodepletionA commercial kit from Sigma was used. This kit contained
a spin column system ﬁlled with afﬁnity-puriﬁed poly-
clonal IgGs and small single-chain antibody ligands attached
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o agarose and allowed the depletion of 20 highly abun-
ant proteins from human plasma or serum. The amount
f proteins was measured before and after each stage of
mmunodepletion with a NanoDrop apparatus. According to
he manufacturer, one stage of immunodepletion is able to
emove 95% of the 20 highly abundant proteins while two
tages of depletion remove 99% of these proteins. Using our
ommercial plasma sample, we  found that 85% and 95% of
he total bulk mass of protein content were removed after one
r two  consecutive depletion steps, respectively (Table 1). The
oncentration determined afterwards on the crude plasma
ample with a Bradford assay [13] was found to be 14% lower
data not shown). The efﬁciency of the immunodepletion pro-
ess was evaluated with LC MS  analysis.
.2.  RP-LC  and  RP/RP-LC  MS/MS
ifferent LC MS/MS  analysis methodologies were applied to
he samples (Fig. 1): 1D-RP-LC MS/MS  with a 70 min  gradient;
D-RP-LC MS/MS  with a 150 min  gradient; and 2D-RP/RP-LC
S/MS  resulting in an analysis time of about 20 h in total.
he 2D-RP/RP-LC MS/MS  workﬂow was not applied to the dou-
ly depleted samples because of the low amounts of sample
vailable after the two depletion stages.
Non-labelled samples were analyzed using a hybrid linear
on trap-orbitrap (LTQ-OT) mass spectrometer with a data-
ependent MS/MS  acquisition method that targeted the 20
ost intense m/z  signals in the MS  survey scans to be furtherragmented with collision-induced dissociation (CID). TMT-
abelled samples were analyzed with a method that targeted
he 10 most intense peaks in the MS  survey scans to be
urther fragmented with CID and higher-energy collisionalomic analyses of human plasma samples.
dissociation (HCD) as reported before for the relative protein
quantiﬁcation with isobaric tags [12].
Every workﬂow was evaluated with respect to the
total number of protein identiﬁcations and unique peptide
matches. The results of the 1D-RP-LC MS/MS  with a 70 min
gradient are given in Table 2a. The best proteome coverage
was obtained when depletion was performed. The same obser-
vation was true for unique peptide matches. Indeed, for the
label-free approach, 1532, 2166, and 1974 unique peptides were
obtained on average for the non-depleted, singly depleted (so-
called 95% depleted according to manufacturer), and doubly
depleted (so-called 99% depleted) samples respectively. For the
TMT-labelled samples, 845, 1221, and 1097 unique peptides
were obtained on average for the non-depleted, 95% depleted,
and 99% depleted samples, respectively.
The results of the 1D-RP-LC MS/MS with a 150 min  gradient
are given in Table 2b. The same tendencies as for the 1D-RP-LC
MS/MS  with a 70 min  gradient were observed, namely that a
higher number of proteins was obtained with depletion and
that the label-free approach provided better proteome cover-
age with respect to the isobaric labelling technology using the
LTQ-OT instrument. For the label-free approach, 2087, 2773,
and 2468 unique peptides were obtained for the non-depleted,
95% depleted, and 99% depleted samples respectively. For the
TMT-labelled samples, 1292, 1778, and 1580 unique peptides
were obtained on average for the non-depleted, 95% depleted,
and 99% depleted samples respectively.
The overlaps between the approaches in terms of proteome
coverage and, in particular, the impact of the depletion of
abundant plasma proteins were evaluated. The Venn diagrams
of Fig. 2 present the number of identiﬁed proteins and their
overlaps for both the label-free and TMT-based approaches.
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Table 2a – Analysis of plasma samples using a 70 min  gradient RP-LC MS/MS  workﬂow (results obtained from 3 LC–MS/MS replicates).
Sample Sample
volume/La
Protocol
description
Sample
preparation
time/hoursb
Quantitative
approach
Multiplexing LC-MS/MS
analysis
time/minc
Number of
identiﬁed
proteins
Number of
unique
peptides
Plasma 2.3 Digestion with trypsin, puriﬁcation 23 Label-free No 100 120  ± 4% 1532 ± 1%
Plasma, 95% depleted 15.3 Depletion, digestion with trypsin,
puriﬁcation
30 154 ± 1% 2166 ± 1%
Plasma, 99% depleted 46 Depletion (2×), digestion with
trypsin, puriﬁcation
32  151 ± 2% 1974 ± 1%
Plasma, TMT-labelled 2.3 Digestion with trypsin, labelling,
puriﬁcation
24 Isobaric
labelling
Yes 80  ± 6% 845 ± 17%
Plasma, 95% depleted,
TMT-labelled
15.3  Depletion, digestion with trypsin,
labelling, puriﬁcation
32  102 ± 3% 1221 ± 5%
Plasma, 99% depleted,
TMT-labelled
46  Depletion (2×), digestion with
trypsin, labelling, puriﬁcation
34  98 ± 6% 1097 ± 8%
a Sample volume to have 100 g proteins available for protein digestion (calculated from Table 1).
b Including bench work, incubations, overnight digestion, and evaporation processes.
c Total time including sample loading/washing, analytical separation and re-equilibration of the LC columns.
Table 2b – Analysis of plasma samples using a 150 min  gradient RP-LC MS/MS  workﬂow (results obtained from 3 LC–MS/MS replicates).
Sample Sample
volume/La
Protocol
Description
Sample
preparation
time/hoursb
Quantitative
approach
Multiplexing LC-MS/MS
analysis
time/minc
Number of
identiﬁed
proteins
Number of
unique
peptides
Plasma 2.3 Digestion with trypsin, puriﬁcation 23 Label-free No 180 154  ± 2% 2087 ± 4%
Plasma, 95% depleted 15.3 Depletion, digestion with trypsin,
puriﬁcation
30 192 ± 1% 2773 ± 3%
Plasma, 99% depleted 46 Depletion (2×), digestion with
trypsin, puriﬁcation
32  194 ± 1% 2468 ± 1%
Plasma, TMT-labelled 2.3 Digestion with trypsin, labelling,
puriﬁcation
24 Isobaric
labelling
Yes 110  ± 3% 1292 ± 1%
Plasma, 95% depleted,
TMT-labelled
15.3  Depletion, digestion with trypsin,
labelling, puriﬁcation
32  129 ± 0% 1778 ± 1%
Plasma, 99% depleted,
TMT-labelled
46  Depletion (2×), digestion with
trypsin, labelling, puriﬁcation
34  123 ± 2% 1580 ± 2%
a Sample volume to have 100 g proteins available for protein digestion (calculated from Table 1).
b Including bench work, incubations, overnight digestion, and evaporation processes.
c Total time including sample loading/washing, analytical separation and re-equilibration of the LC columns.
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Fig. 2 – Number of proteins identiﬁed using RP-LC MS/MS
with 150 min  gradient RP-LC MS/MS  workﬂow. Both
label-free (a) and TMT-based (b) approaches were  assessed.
Plasma protein samples were  prepared without any
abundant-protein depletion (Plasma), or with
abundant-protein depletion performed once (Plasma, 95%
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Fig. 3 – Number of proteins identiﬁed using a 2D-RP/RP-LC
MS/MS workﬂow. Both label-free and TMT-based
approaches were assessed and compared. Plasma protein
samples were prepared without any abundant-protein
depletion (Plasma and Plasma, TMT-labelled) or with
abundant-protein depletion performed a single time
(Plasma, 95% depleted and Plasma, 95% depleted,epleted) or twice (Plasma, 99% depleted).
verall, 135 and 89 proteins were found in common between
he non-depleted, 95% depleted, and 99% depleted samples
or the label-free and TMT-based approaches respectively,
orresponding to an overlap of 52% and 51% with respect
o all identiﬁed proteins. In general, the tandem depletion
i.e., 99% depleted samples) provided the highest numbers
f new/unique protein identiﬁcations with 30 and 22 pro-
eins exclusively identiﬁed with the label-free and TMT-based
pproaches respectively. Interestingly, there was no protein
dentiﬁcation uniquely common to the non-depleted and 99%
epleted samples.
Finally, a 2D-RP/RP-LC MS/MS  workﬂow was applied.
ecause of the low sample amount left after the double deple-
ion (i.e., 87 g; see Table 1), the doubly depleted plasma sample
i.e., 99%) was not analyzed with 2D-RP/RP-LC MS/MS. 2D-
P/RP-LC MS/MS  enabled a deeper coverage of the plasma
roteome and a total 288 and 392 proteins were identiﬁed in
he non-labelled depleted and 95% depleted plasma samplesTMT-labelled).
within duplicate MS analyses (Fig. 3, Table 2c and Supplemen-
tary data). The Venn diagram of Fig. 3 compares the results of
the 2D-RP/RP-LC MS/MS analyses. An overlap of 147 proteins
was found between all these analyses.
Altogether, these proteomic analyses identiﬁed 437 protein
entries with stringent criteria in the studied human plasma
sample (see Supplementary data). Good sequence coverage
was achieved with an average of more  than 12 unique peptide
matches per protein and a median of 7 unique peptides per
protein. Classical plasma proteins were identiﬁed. We com-
pared our protein list with the one recently reported by Farrah
et al. [14].
4.  Discussion
This work aimed at providing guidance for the choice of
proteomics workﬂows to analyze human plasma samples
and several workﬂows were assessed. Single immunodeple-
tion combined with the use of longer RP-LC gradients and
columns demonstrated proteome coverage of 192 and 129 pro-
teins on average for the label-free and label-based approaches,
respectively, at a manageable effort and throughput (i.e., RP-LC
MS/MS  analysis of 3 h per sample) when applied to hundred
or more  samples, e.g., in clinical studies.
4.1.  Investment  vs.  total  protein  identiﬁcations
2D-RP/RP-LC MS/MS was shown to result in the best proteome
coverage (i.e., number of protein identiﬁcations). RP/RP-LC was
previously shown to be a powerful alternative to the classi-
cal strong-cation exchange (SCX)/RP-LC [9]. In particular, the
RP/RP-LC workﬂow eliminates the need for sample desalt-
ing, resulting in reduced sample losses and processing time
together with a better resolution and peak capacity than
with SCX [23]. Nonetheless, the long analysis time was a
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signiﬁcant drawback that precludes the general application
of such upstream fractionation in large clinical studies.
The better proteome coverage obtained with the label-free
approach may depend on the speed of the MS/MS  acquisition
method (see Section 2). This fact is illustrated by the number
of CID tandem mass spectra performed during analysis. For
example, the average numbers of CID scans/spectra that were
performed and used for peptide matching by the database
search engine were 40′569 and 29′840 for the non-labelled and
TMT-labelled plasma samples respectively (analysis with 1D-
RP-LC MS/MS  using a 150 min  gradient). On the other hand,
the quantiﬁcation with TMTs offers multiplexing that signif-
icantly reduces the overall analysis time and, because the
labelling occurs early in the analytical workﬂow the experi-
mental variance for the quantiﬁcation is reduced [15]. These
advantages are highly relevant in the context of large clini-
cal discovery studies. In terms of investment (which include
instrument time/depreciation, and reagent costs), we found
that – despite the investment in the tagging reagents – the
sixplex isobaric tagging approach was about 10% less expen-
sive than the label-free strategy. The decrease of the analysis
time is indeed roughly inversely proportional to the multi-
plexing capabilities of the isobaric tags. On the top of that,
if consider the workforce needed to analyze the samples and
process the data, the cost savings should be even larger with
the multiplexed approach.
The immunodepletion and RP-LC MS/MS  analysis are con-
sidered as the limiting steps in terms of throughput while the
rest of the sample preparation can be performed in a paral-
lelized fashion (i.e., reduction/alkylation/digestion, labelling,
and puriﬁcation). Immunodepletion can be performed with
the column mounted onto an LC system but – as with RP-
LC MS/MS analysis – only one sample can be processed at a
time. Multiplying the number of instruments (LC systems and
mass spectrometers) remains a very costly option while the
possibility to label at protein level and enhanced multiplexing
capabilities may be cost-efﬁcient alternatives [16–18].
With regard to the reproducibility of the results, we
assessed here the LC MS/MS experiments and showed that
the numbers of both identiﬁed proteins and unique peptides
varied less than 5% on average between technical replicates.
The reproducibility, the pros and the cons of the individual
analytical techniques (i.e., immunodepletion, tryptic diges-
tion, isobaric tagging, and LC fractionation) were not evaluated
herein but were reported and discussed previously [9,19–23].
The use of internal standards is important in that respect to
not only evaluate but also correct for experimental bias and to
normalize the data.
4.2.  Investment  vs.  speciﬁc  protein  identiﬁcations
As expected, some proteins were only identiﬁed with one
or another of the depletion strategies (i.e., absence of deple-
tion, 95% depletion, and 99% depletion) (Fig. 2a). The 17
proteins identiﬁed uniquely in the non-depleted samples
were mainly immunoglobulin chains in addition of poly-
meric immunoglobulin receptor (PIGR), titin (TITIN) and
complement C1q subcomponent subunit A (C1QA) for the
label-free approach. Likewise, for the tagging-based strategy,
7 immunoglobulin chains were identiﬁed in the non-depleted
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amples only, in addition to complement C1q subcompo-
ent subunit B (C1QB), dynein heavy chain 10 (DYH10), and
ransthyretin (TTHY) (Fig. 2b). These results appeared consis-
ent as the immuno-based depletion targeted the removal of
lbumin, IgG, TTHY, ﬁbrinogen, IgA, 2-marcroglobulin, IgM,
1-antitrypsin, complement C3, haptoglobulin, apolipopro-
ein A1, apolipoprotein A3, apolipoprotein B, 1-acid glyco-
rotein, ceruloplasmin, CO4B, C1QA, IgD, prealbumin, and
lasminogen. But it clearly showed that immunoafﬁnity
epletion efﬁciency is partial only. The identiﬁcation of
YH10 was rather unexpected as it was not targeted by the
mmunoafﬁnity capture. This observation probably resulted
rom the stochastic nature of the data-dependant MS  acqui-
ition methodology. Despite the fact that the removal of the
0 proteins listed above appeared to be efﬁcient, the concomi-
ant unspeciﬁc removal of other proteins cannot be entirely
xcluded but was not evaluated in the present work [24]. The
eader is referred to the manufacturer’s speciﬁcations. Many
roteins were uniquely identiﬁed when depletion was per-
ormed (see Supplementary data for the complete list). For
nstance, intercellular adhesion molecule 1 (ICAM1) was iden-
iﬁed. ICAM1 was previously reported in the ng mL−1 range in
uman plasma samples as molecular markers for atheroscle-
osis [25] and stroke [26,27]. Peroxiredoxin-2 (PRDX2), which
as recently reported to be increased in the microdialysates
f the infarct core of stroke patients, was another example
Fig. 2a) [28] as well as prostaglandin-H2 D-isomerase (PTGDS)
hich was shown previously to be linked to brain disorders in
erebrospinal ﬂuid [29].
.3.  Proteome  coverage  overlap  between  workﬂows
he protein overlap between label-free and isobaric labelling
pproaches was relatively small when using 2D-RP/RP-LC
S/MS  (i.e., 147 proteins). This observation was mainly due
o the fact that the 2D-RP/RP-LC MS/MS  analysis of the
rude plasma labelled with TMT  only identiﬁed 163 proteins
Fig. 3). With a higher degree of upstream fractionation, the
abel-free approach proved again superiority in terms of qual-
tative results (i.e., number of peptides and protein identiﬁed).
onetheless, the quantitative advantages offered by isobaric
agging when upstream fractionation is performed must be
ointed out. The 212 proteins identiﬁed in the 95% depleted
lasma sample labelled with TMT  would have also been quan-
iﬁable straightforwardly.
Over the 437 protein entries found in this dataset, 353
ave been recently reported in the human plasma PeptideAt-
as reference set that encompassed 1929 canonical protein
equences [14]. Thirty one of these shared proteins between
hese datasets were reported in the ng mL−1 range in human
lasma by Farrah et al. [14].
.  Conclusions
n evaluation of several proteomic workﬂows was performed
or the analysis of human plasma samples. Extensive sample
reparation and fractionation are necessary to signiﬁcantly
ncrease proteome coverage. However, investments must be
imited when it comes to realistic workﬂow deployment in 1 ( 2 0 1 3 ) 8–16 15
large clinical studies. Multi-afﬁnity depletion of highly abun-
dant proteins was efﬁcient to access lower abundance proteins
in plasma. Proteins at a concentration of ng mL−1 range were
conﬁdently identiﬁed. The use of longer RP-LC gradients and
columns appeared as a very valuable solution in terms of
a good compromise between effort, throughput and repro-
ducibility. While this option increases LC MS/MS  analytical
time, it does not require any supplemental human workforce
and sample handling. As regards the relative protein quan-
tiﬁcation between samples, isobaric tagging is recommended
because of the multiplexing capabilities that signiﬁcantly
reduce the overall analysis time and technical variability. For
large-scale clinical studies the following workﬂow appears to
us both feasible and efﬁcient: (i) abundant-protein immun-
odepletion; (ii) reduction/alkylation/digestion of the proteins;
(iii) isobaric labelling of the peptides; and, (iv) RP-LC MS/MS
analysis of the samples using long gradients and columns. We
are now evaluating the analytical performance of a complete,
integrated human plasma proteomics workﬂow (based on the
elements described and assessed in this paper) and have auto-
mated most of the sample preparation steps using LC systems
for the immunodepletion and liquid handling robotics for the
reduction/alkylation/digestion, isobaric labelling, and sample
puriﬁcation.
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